| PORP | partial ossicular replacement prosthesis |
|---|---|
| PVR | peripheral vascular resistance; perspective volume rendering; poliovirus receptor; postvoiding resid... |
| RCM | radial contour model; radiographic contrast medium; red cell mass; reinforced clostridial medium; re... |
| SIR | single isomorphous replacement; specific immune release; standardized incidence ratio; syndrome of i... |
| TARA | total articular replacement arthroplasty; tumor-associated rejection antigen |
| chelation therapy | Therapy of heavy metal poisoning using agents which sequester the metal from organs or tissues and bind it firmly within the ring structure of a new compound which can be eliminated from the body. (12 Dec 1998) |
|---|---|
| growth hormone | <endocrinology, hormone> Polypeptide (191 amino acids) produced by anterior pituitary that stimulates liver to produce somatomedins 1 & 2. (13 Nov 1997) |
| growth hormone-producing adenoma | <tumour> An adenoma that produces the clinical picture of gigantism or acromegaly, although a third of the cells have no granules or are a mixture of acidophils and chromophobes; some tumours may secrete both growth hormone and prolactin; often an acidophil or eosinophil adenoma. (05 Mar 2000) |
| growth hormone-releasing factor | <endocrinology> Peptide hormone related to the glucagon family, released from the pituitary, acts on the adenohypophysis to release growth hormone. Synonym: somatoliberin, growth hormone-releasing factor. (20 Sep 2002) |
| growth hormone stimulation test | <investigation> A test which measures the level of human growth hormone in response to the administration of the amino acid arginine. This test measures the ability of the pituitary gland to secrete growth hormone. Normal values in children are: 48 ng/ml. Normal values in men are 10 ng/ml. Normal values in women are 15 ng/ml. This test is used to evaluate infants with growth retardation. It may also be part of an evaluation for a pituitary tumour. Failure of arginine to raise growth hormone levels may indicate hypopituitarism or dwarfism. (27 Sep 1997) |
| growth hormone suppression test | <investigation> A test to determine if growth hormone is suppressed by hyperglycaemia. Growth hormone blood levels are determined sequentially after ingestion of a glucose-rich meal. If growth hormone levels remain elevated (after the glucose is given) then acromegaly or gigantism is suspected. (27 Sep 1997) |
| chorionic gonadotrophic hormone | A glycoprotein with a carbohydrate fraction composed of d-galactose and hexosamine, extracted from the urine of pregnant women and produced by the placental trophoblastic cells; its most important role appears to be stimulation, during the first trimester, of ovarian secretion of the oestrogen and progesterone required for the integrity of conceptus; it appears to play no significant role in the last two trimesters of pregnancy, as the oestrogen and progesterone are then formed by the placenta. Synonym: anterior pituitary-like hormone, choriogonadotropin, chorionic gonadotropic hormone, chorionic gonadotrophic hormone, placenta gonadotropin, placentagonadotropin. (05 Mar 2000) |
| chorionic growth hormone-prolactin | human placental lactogen |
| root canal therapy | A treatment modality in endodontics concerned with the therapy of diseases of the dental pulp. For preparatory procedures, root canal preparation is available. (12 Dec 1998) |
| chromatophorotropic hormone | See: melanotropin. (05 Mar 2000) |
| rotation therapy | Teletherapy in which a desirable radiation dose distribution is achieved by rotating the patient or machine about an axis passing through the centre of the tumour. (05 Mar 2000) |
| microwave therapy | Treatment with high frequency radiations of 3,000,000,000 Hz (3000 MHz), at a wavelength of 10 cm. Synonym: microwave therapy. Origin: micro-+ G. Kyma, a wave, + therapeia, treatment (05 Mar 2000) |
| milieu therapy | A treatment program based on manipulation of the patient's environment by the medical staff. The patient does not participate in planning the treatment regimen. (12 Dec 1998) |
| photodynamic radiation therapy | <oncology, technique> A light sensitive drug is given through a vein and concentrates in the tumour. Then, during a surgical procedure, a special light activates the drug. The activated drug kills tumour cells. (31 Dec 1997) |
| photodynamic therapy | <oncology, technique> Cancer treatment that uses the interaction between laser light and a substance that makes cells more sensitive to light. When light is applied to cells that have been treated with this substance, a chemical reaction occurs and destroys cancer cells. (31 Dec 1997) |